Actavis Said to Pay $12 Million to Settle Digitek Lawsuits

Actavis Group hf, a maker of generic drugs, will pay at least $12 million to resolve claims that the company failed to warn consumers that its Digitek heart drug was defective, according to people familiar with the settlement.

To contact the reporters on this story: Jef Feeley in Wilmington at; Sophia Pearson in Wilmington, Delaware

Bloomberg reserves the right to edit or remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.